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Summary 
When B cells are deprived of signaling through CD40, 
they exhibit the ability to induce T cell tolerance. The 
in vivo administration of antigp39 and aliogeneic B 
cells diminished the ability of mice to mount an alloge- 
nelc response. Tolerance induction was specific for 
the haplotype expressed on the allogeneic B cells. Se- 
lective ailospecific unresponsiveness was induced in 
the CD8 and CD4 compartments by the administratlon 
of antigp39 and class ii-deficient B cells or class 
I-deficient B cells, respectively. As predicted by stud- 
ies with anti-gp39 treatment, diminished allospecific 
responsiveness was induced by the administration of 
B cells to mice genetically deficient in gp39. Taken 
together, these data are consistent with the premise 
that deprivation of CD40 signaling engenders B cells 
with enhanced tolerogsniclty. These studles provide in- 
sights into the tolerogenic capaclty of resting B ceils and 
outlines a practical approach to exploit this function. 
Introduction 
The activation of naive T ceils exclusively through the T 
cell antigen receptor (TCR) without engagement of other 
T helper (Th) costimulatoty molecules results in Tcell unre- 
sponsiveness (Schwartz, 1992; Linsley and Ledbetter, 
‘Present address: ImmunexCorporation, 51 University Street, Seattle, 
Washington 99121. 
1993). Costimulatory molecules, like 87-l and 87-2, 
through binding to theircounterreceptorson Tcells (CD28, 
CTLA4), heighten lymphokine production, promote T cell 
expansion, and prevent the induction of Tcell anergy (Har- 
ding et at., 1992; Schwartz, 1990; Koulova et at., 1991). 
The capacity of antigen-presenting cells (APCs) to induce 
T cell activation proficiently hinges upon the density of 
the costimulatory molecules that are expressed. Although 
some professional APCs may constitutively express high 
densities of costimulatory molecules (Liu et al., 1992; 
Freedman et al., l991), resting B cells do not and this is 
believed to be the primary reason for their incompetent 
APC function (Kreiger et al., 1985; Finkelman et al., 1992; 
Parker, 1993). While it is clear that resting B cells are 
ineffective at positively triggering T cell responses, only 
a limited number of studies havedemonstrated that resting 
B cells induce T cell tolerance. In vitro, it has been shown 
that B cells can render T cell clones unresponsive to sub- 
sequent antigenic challenge (Gilbert and Weigle, 1994; 
Hori et al, 1989). In vivo, the tolerogenic capacity of B cells 
has been demonstrated in only two instances. First, it has 
been shown that the administration of male antigen- 
bearing (HY) B cells to female mice induced cytotoxic T 
lymphocyte (CTL) unresponsiveness to HY (Fuchs and 
Matzinger, 1992). in another case, it was shown that a 
monomeric rabbit anti-& preferentially targeted to resting 
B cells, induced T cell tolerance to the heterologous rabbit 
immunoglobulin (Eynon and Parker, 1992). In spite of 
these successes, repeated attempts to broaden the use 
of resting B cells to induce tolerance to a greater diversity 
of antigens have been unsuccessful. As studied here, for 
example, the administration of resting allogeneic B cells 
does not induce allospecific tolerance in the host. 
One limitation for the use of B cells to induce tolerance 
in vivo may be the ease with which they acquire “profes- 
sional” APC capacities upon transfer, and therefore lose 
their tolerogenic potential. It is anticipated that upon entry 
into the host, antigen-bearing B cells are acted upon by 
the immune system of the host and triggered to up- 
regulate APC activities. Although it is not clear which host 
mediators elicited by administration of B cells can enhance 
their APC function in vivo, a plethora of activities can alter 
B cell costimulatory molecule expression and the APC 
function of B cells in vitro. In vitro B cell APC function is 
dramatically enhanced by mitogenic stimulation by lipo- 
polysaccharide (LPS), soluble gp39 (Kennedy et al., 1994; 
Roy et al., 1994), and anti-immunoglobulin (Lenschow et 
al., 1994). For the most part, the transition to a competent 
APC is accompanied by an increase in the density of 87-2. 
However, in vivo it is not clear what signals are critical for 
inducing the transition of resting B cells from an incompe- 
tent APC to a competent APC. 
The studies in this report focus on the role of CD40 in 
triggering resting B cells to become professional APCs. 
The system developed to investigate this issue measures 
the ability of allogeneic B cells to elicit alloreactive CD4+ 
and CD8+ T cells when the allogeneic B cells are deprived 
Immunity 
646 
sb . a gp39 a&9 HIg ab -  
II cells -  + + B cells . 
a  gp390 ,y9 Hlg 
-  + 
Figure 1. Administration of Allogeneic 6 Cells and Antigp39 Inhibits 
the Response of CD4 T Cells in an MLR 
Allogeneic splenic B cells from C57BU6 (H-2b) mice were injected 
(intravenously) into recipient BALB/c (H-2’) mice, which were treated 
(intraperitoneatly) with either antigp39 or Hlg every 2 days for 10 days. 
On day 12, spleen cells were isolated and used as responders in a 
21 ratio to stimulators in an MLR assay. In (A), B cells were separated 
either by Percoll or Ficoll gradient. The groups are as follows: closed 
bars, naive control; shaded bars, resting Percoll-fractionated B cells; 
striped bars, Ficolled B cells. Responders were stimulated with spleen 
cells from either (A, B) C57BU6 mice or (C) BiO.BR mice, H-2k. Results 
are representative of pooled spleens from 2 mice in each group and 
eight experiments. p values were determined by BtudenPs t test using 
the WormStat (version 2.0) program. 
of a CD40 signal. The hypothesis set forth in this study 
suggests that if the gp39 function of the host is either 
blocked by antibody (antigp39) or abolished by targeted 
deletion of the gene, then allogeneic 6 cells will be unable 
to up-regulate the expression of costimulatory molecules. 
This lack of costimulation hinders allospecific responses 
and will induce host-allospecific T cell unresponsiveness. 
This hypothesis is based on the premise that gp39 is the 
primary regulator of B cell APC function in vivo and that 
other agonists cannot replace this function. Data pre- 
sented show that the coadministration of antigp39 and 
allogeneic B cells, or the administration of allogeneic B 
cells alone to gp39deficient mice, diminishes allospecific 
CD4 responsiveness, CD8 responsiveness, or both. Toler- 
ance induced by antigp39 is not observed if allogeneic 
tumor cells or thymocytes are used as immunogens, indi- 
cating that the unresponsiveness is dependent upon the 
administration of nonactivated B cells. Using allogeneic 
B cells from mice deficient in class I or class II major histo- 
compatibility complex (MHC) expression, it is shown that 
the induction of CD4 and CD8 hyporesponsiveness is de- 
pendent on expression of the relevant MHC antigen on 
the B cell and that the induction of hyporesponsiveness 
in each compartment is independent of the other MHC 
molecule. Results also indicate that when animals are pre- 
tolerized to Fl alloantigens, spleen cells from these mice 
are unable to induce graft-versus-host disease (GVHD) 
upon adoptive transfer. These studies present a novel ap 
preach to exploit the tolerogenic potential of resting B cells 
to induce allospecific tolerance and underscore the im- 
portant and active contribution of the host in regulating the 
APC function of donor cells via gp39-CD40 interactions. 
Results 
Administration of Antigp39 with Allogeneic B Cells 
lnhlblts the Mixed Lymphocyte Response 
The premise being tested in this investigation asserts that 
if resting allogeneic B cells are kept in a quiescent state 
by blocking CD46mediated activation, allospecific unre- 
sponsiveness will be induced. To test this hypothesis, allo- 
geneic B cells from H-2b (C57BU6) mice were adminis- 
tered to allogeneic H# recipients (BALB/c) in the 
presence of antigp39 or hamster immunoglobulin (Hlg). 
After 12 days, the allospecific mixed lymphocyte response 
(MLR) was measured. Mice administered allogeneic B 
cells (H-2q and control Hlg had a slightly elevated MLR 
to the relevant alloantigen, H-2b. In contrast, the combined 
administration of allogeneic B cells (H-p) and antigp39 
reduced responses in the MLR to levels below that of the 
naive MLR (Figure 1 B). The responses of cells from ani- 
mals receiving B cells alone were identical to control Hlg- 
treated animals (data not shown). The in vivo administra- 
tion of ant&p39 alone had no impact on the responses 
in the MLR to H-2b. Furthermore, the diminished MLR im- 
posed by the coadministration of H-2b B cellsand antigp39 
was specific for the H-2b alloantigen, since the MLR of 
these cells to H-2lrbearing stimulators was unaltered (Fig- 
ure 1C). These studies show thatThe MLR to specific allo- 
antigens can be reduced by the coadministration of alloan- 
tigen-bearing B cells and antigp39. 
Experiments were performed to evaluate the respective 
efficacy of T-depleted spleen cell preparations and highly 
purified resting B cell preparations for the induction of T 
cell unresponsiveness when coadministered with anti- 
gp39. First, the in vivo administration of neither B cells 
nor resting B cell preparations caused a diminished in vitro 
MLR (Figure 1A). Second, when coadministered with anti- 
gp39, resting B cell populations were only marginally more 
effective than the T-depleted cell populations at low num- 
bers of cells (5 x W/mouse) at inducing diminished MLR. 
Antigp39 Prevents the lnductlon of Allospecific 
CTL by Allogenelc B Ceils 
A panel of allogeneic B cells from H-2b (C57BL/6), H@ 
(BALB/c), and H-2k (BlO.BR) were administered to alloge- 
neic recipients, either BALBlc or C57BU6, in the presence 
or absence of anti-gp39. The CTL response to donor allo- 
antigen was measured 5 days after immunization by a 
standard %r release assay. Responses to H-2b, H-p, and 
H-2k were induced by the administration of the respective 
allogeneic B cells in the absence of antigp39. In contrast, 
mice that received anti-gp39 and allogeneic cells did not 
generate CTL in vivo in response to allogeneic B cells 
(Figure 2). As presented above, no differences were ob 
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Figure 2. Antigp39 Prevents the Induction of Allospecific CTL by Allo- 
geneic B Cells 
Allogeneic splenic B cells from C57BUB (A), BALBk (6) and BlO.BR 
(C) were injected (intravenously) into BALBk (A and C) and C57BU 
6 (B) recipients and administered either Hlg or antigp39 (250 pg/ 
mouse intraperitoneally on days 0.2, and 4). On day 6, spleens were 
removed and used as effector cells to determine CTL responses 
against H-2b (A), H-p (B), and H-2* (C). Targets used in these assays 
were P615 (H-29, E female Kl (H-2q, and SL6 (H-27. Groups repre- 
sented are untreated (cfosed square), antigp39 treated (closed trian- 
gle), and naive mice (closed circle). Results are representative of 3 
mice in each group and the experiment presented is representative 
of five experiments. 
served between tolerogenic capacity of T-depleted spleen 
cells and high density Percoll-fractionated B cells (data 
not shown). 
The Coadmlnistratlon of Anti-@9 and Allogeneic 
B Cells In Vivo Reduces the Secondary CTL 
Response In Vitro 
Secondary in vitro CTL responses were measured from 
naive mice and mice immunized with allogeneic B cells 
and treated with antisp39 or Hlg. After 12 days, spleen 
cells from treated mice were stimulated in vitro with HZ’ 
Figure 3. The Coadministration of Antigp39 and Allogeneic B Cells 
In Vivo Prevents the Secondary Anti-Allospecific CTL Response 
In Vitro 
(A) Specific alloresponses in vitro of mice treated with allogeneic B 
cells. BALB/c mice were primed in vivo with H-p-bearing B cells, as 
described in Figure 1. Spleens from the antigp39 and Hlg-treated 
mice were cultured for 5 days with H-2b or H-2d stimulators. After 5 
days, the responder cells were assayed for CTL activii against P615 
(H-2$ syngeneic control, data not shown) and E female Kl (H-p). 
Groups are unstimulated (open diamond), naive (open square), anti- 
gp39 alone (closed circle), B cells and antigps9 (closed triangle), and 
B cells and Hlg (open triangle). Results are representative of eight 
experiments with pooled spleens from 2 mice in each group. 
(B) Anti- H-PkCTL responses(third party)from mice treated with alloge- 
neic B cells. Spleen cell cultures as in (A) were analyzed for anti-H-P 
allogeneic responses using BlO.BR (H-27 spleen cells as the stimula- 
tors and SL6 (SL8, H-a as the targets in the CTL assay. Groups 
are unstimulated (open diamond), naive (open square), B cells and 
antigp39 (closed triangle), and B cells and Hlg (open triangle). 
B cells for 6 days and CTL responses determined. As antic- 
ipated, in vivo immunization of mice with H-2b B cells and 
Hlg resulted in a high titered secondary anti-H@ CTL re- 
sponse in vitro (Figure 3A). The heightened secondary 
anti-H-2b CTL response was not observed using lympho- 
cytes derived from mice immunized with allogeneic B cells 
and antigp39 in vivo. The response of mice given anti- 
gp39 and H-2b-bearing B cells was lower than that of naive 
mouse cells cultured in vitro. The lowered CTL response 
is dependent on alloantigen and anti-gp39, since the re- 
sponse of mice treated with antigp39 alone is indistin- 
guishable from the response of naive cells cultured 
in vitro. 
To assess whether the administration of antigp39 and 
allogeneic B cells altered the CTL response to a third party 
alloantigen, lymphocytes from mice treated with H-2b B 
cells with or without antigp39 were stimulated in vitro with 
H-2’rbearing cells and assayed against an H-2k-bearing 
target (Figure 38). Results show that the CTL response 
to a third party alloantigen-bearing target was unaltered 
by the administration of antigp39 and allogeneic B cells. 
Taken together, these data show that the administration 
of alloantigen-bearing B cells and antigp39 can diminish 
CTL reactivity to specific alloantigens. 
Alteration of the Tolerogenlc Capaclty of B Cells 
by Stimulation with LPS 
The minimal APC function of B cells is believed to contrib- 
ute to the tolerogenic effects observed in the presence of 
antigp39. Stimulation of S cells with LPS has been shown 
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Figure 4. LPS-Activated B Cells Can Not Induce Tolerance in CD4 T 
Cells When Administered with Antigp39 
Unstimulated B cells or O-day-activated LPS (50 kg/ml) blasts were 
injected (intravenously) and treated with antibody as described in Fig- 
ure 1. On day 12. spleens were removed and the cells were used 
as responders in an MLR. Results shown are representative of three 
experiments with pooled spleens from 2 mice in each group. 
Therefore, it was of interest to determine whether prior 
activation with LPS would alter the tolerogenic capacity 
of allogeneic 6 cells administered to mice together with 
antigp39. Allogeneic B cells were activated in vitro with 
LPS for 2 days and then administered to mice with or 
without antigp39. The administration of allogeneic B cells 
or allogeneic LPS blasts “primed” the MLR equally, caus- 
ing an approximate 50% increase in the MLR (Figure 4). 
The coadministration of antigp39 resulted in a diminished 
MLR with either of the B cell sources, but B cells caused 
agreater reduction in the response than LPS blasts. Solely 
based on proliferative responses, it appeared that in the 
presence of antigp39, the B cells tolerized the MLR and 
the LPS blasts failed to prime the MLR. Therefore, the 
preactivation of allogeneic B cells does reduce their abil- 
ity to mediate allospecific T tolerance in the presence of 
anti-gp39. 
Anti-gp39 Does Not Inhibit the Allospeciflc CTL 
Response When Allogenelc T Cells or Allogeneic 
Tumor Cells Are Used as lmmunogens 
To evaluate whether ant&p39 was interfering broadly 
with the generation of allospecific CTL, other alloantigen- 
bearing cells were used as immunogens. Allogeneic thy- 
mocytes and P815 (H-p) tumor cells were administered 
to mice with or without anti-gp39 and the allospecific CTL 
response measured. Figure 5 shows that antigp39 did 
not diminish the primary in vivo CTL response elicited by 
either allogeneic thymocytes (Figure 5A) or allogeneic tu- 
mor cells (Figure 58); however, treatment with B cells and 
anti-gp39 did reduce by >80% the CTL response to alloge- 
neic B cells. Although the magnitude of the CTL response 
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Figure 5. Antigp39 Has No Effect on the In Vivo Priming of Mice with 
Allogeneic Thymocytes or Tumor Cells 
(A) Response to allogeneic thymocytes. BALB/c mice (H-q were im- 
munized with thymocytes (50 x IOYrecipient) or B cells (50 x l(P/ 
recipient) from C57BU6 mice (H-2b) and then either Hlg treated or 
antigp39 treated (250 uglmouse intraperitoneally on days 0, 2, and 
4). On day 6, CTL responses were measured. Groups are the following: 
thymocytes and Hlg (closed square) or antigp39 (closed circle); B 
cells and Hlg (open square)or antigp39 (open circle); no immunization 
(closed triangle). Target cells used in this assay were E female 
Kl(H-2b). The results are representative of three such experiments. 
(B) Response to allogeneic tumor cells. C57BU6 mice (H-26) were 
immunized intraperitoneally with P615 tumor cells (50 x lC%ecipient; 
H-8 in the presence or absence of antigp39 (administered on days 0, 
2,4,6,6, and 10). On day 12, mice were sacrificed and CTL responses 
measured against H-2’-bearing target (P615). Groups are nonimmune 
(closed square), P615 cells (closed circle), P615 and antigp39 (open 
triangle). Results are representative of two experiments with pooled 
spleens from 3 mice in each group. 
trials (3), no diminution of the CTL response was observed 
by the administration of antigp39. Therefore, it appears 
that the inhibitory effect of anti-gp39 was limited by the 
nature of the cell type used (8 cells) for immunization. 
B Cells Are Tolerogenic Without,a CD46 Signal 
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Figure 6. Class II Molecules on B Cells Are Required to Tolerize CD4 
T Cells and Class I Molecules on B Ceils Are Required to Tolerize 
CD8 T Cells 
Donor B cells were prepared from either class II or p2rn knockout mice. 
These were used along with wild-type B cells in the immunizing proto- 
col described in Figure 1. After 12 days, spleens were removed and 
restimulated in vitro with wild-type spleen cells. 
(A) Class II knockouts. Mice were immunized with either wild-type or 
class II- (II-) B cells; the ability of antigp39 and B cells to tolerize CD4 
T cells was measured in an MLR. 
(8) Recipient spleens were cultured for 6 days in the presence of 
wild-type allogeneic spleen cells and the ability of donor B cells to 
tolerize CD8 T cells was measured in a CTL assay directed against 
E female Kl target cells. Groups refer to the immunizing protocol and 
are as follows: naive (open square), wild-type B cells plus antigp39 
(closed triangle), II- B cells plus antigp39 (closed circle), wild-type B 
cells plus Hlg (open triangle), and II‘ B cells plus Hlg (open circle). 
(C) bnrn knockouts. Mice were immunized with either wild-type or &rn 
knockout &m-) B cells and the ability to tolerize CD4 T cells, in the 
presence of anti-gp39, was determined in an MLR. 
(D) Responders were stimulated and used in a CTL assay as described 
for(B). Groups represent the immunizing protocol and are as follows: 
naive (open square), wild-type B cells plus antigp39 (closed triangle), 
Prim- B cells plus anti-gp39 (closed circle), wild-type I3 cells plus Hlg 
(open triangle) and Brim- 6 cells plus Hlg (open circle). Experiments 
are representative of pooled spleens from 2 mice per group and three 
different experiments. 
Class II and Class I Molecules Are Required to 
Tolerize the CD4 and CD8 Alloreactive T Ceil 
Compartments, Respectively 
To evaluate whether anti-gp39-mediated tolerance in the 
CD4 and CD8 compartments was interdependent, we uti- 
lized class II and p-2 microglobulin &m) knockout mice 
as a source for allogeneic tolerogenic B cells. The coad- 
ministration of anti-gp39 and allogeneic B cells derived 
from class II- mice did not diminish the MLR, (Figure 6A), 
yet did reduce the class l-restricted CTL response (Figure 
6B). The reductionsof the CTL response mediated by wild- 
type and class II- B cells in the presence of anti-gp39 were 
indistinguishable. 
Using B cells from mice deficient in b2m, the role of 
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Figure 7. Administration of Allogeneic B Cells to gp39 Knockout Mice 
Causes Tolerance to In Vitro Challenge with Alloantigen 
B cells were prepared from BALE/c mice and injected’(intravenously) 
into either gp39 knockouts (-I-) or wild-type controls (+/+). On day 
12, spleens were used as responders in an MLR. A representation of 
four experiments with a total of 8 mice per group is shown. 
class I MHC molecules in MLR and CTL responses was 
addressed. When mice deficient in Prim were used as a 
source for allogeneic B cells, the MLR was unaffected by 
the lack of class I on the surface of the allogeneic B cells 
and the responses were identical to responses generated 
with wild-type B cells (Figure 6C). However, if class I was 
absent, coadministration of B cells and anti-gp39 did not 
induce tolerance in the CTL response (Figure 6D). To- 
gether, these data indicate that tolerance in the CD4 and 
CD6 T cell compartments is induced independently. 
Administration of Allogenelc B Cells to gp89 
Knockout Mice Leads to Diminished 
Allogenelc Responses 
To dismiss the potential contribution of the anti-gp39 
monoclonal antibody to alterations in alloreactive T cell 
responsiveness, the effect of administration of allogeneic 
B cells to gp39 knockout mice was evaluated. Allogeneic 
B cells (H-2) were prepared and injected into either gp39 
knockout or wild-type control mice. The MLR of gp39 
knockout mice was similar to that observed with wild-type 
recipients (Figure 7). Prior administration of allogeneic B 
cells to the gp39 knockout mice inhibited the normal re- 
sponse to alloantigen X0%. This inhibition was only seen 
in the gp39 knockouts and not the wild-type controls. 
The Coadministration of Antigp39 and Allogenelc 
B Cells Renders CTL Incapable of Mounting a 
Graft versus Host CTL Response In Vltro or In Vivo 
To evaluate more fully the functional capacity of the unre- 
sponsive CTL from mice rendered tolerant to alloantigen, 
the tolerized cells were challenged both in vivo and in vitro. 
C57BU6 mice (H-2q were administered Fl spleen cells 
(H-2”) with or without anti-gp39, with the goal of inducing 
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Figure 8. Transfer of Fl Spleen Cells to Antigp30Treated Parental 
Mice Induces Tolerance as Measured In Vitro and In Vivo 
(A)Transfer of pretolerized C57BU6 cells does not induce acute GVHD 
when donor animals are treated with antigp39. Approximately 60 x 
IO’ spleen cells from C57BU6 mice administered B6D2Fl spleens in 
the presence or absence of antigp99 were transferred into B6D2Fl 
animals in a model for acute GVHD. H-2b anti-H-2d CTL responses 
were determined using the %r release assay using p615 (H-2d) as 
the target cell line. Groups represented are transferred spleens from 
animals treated with Fl spleen cells plus antigp69 (closed square), 
Fl cells and no antibody (closed circle), or transfer of naive C57SU6 
spleen cells in the normal induction of acute GVHD (closed triangle). 
(B) Antigp39 reduces the CTL H-2b anti- H-2d response when in vivo- 
primed spleens are rechallenged in vitro with B6D2Fl spleens. 
C57SU6 were immunized intravenously with 100 x 1Q S6D2Fl 
spleen cells on day 0, and then not treated (closed circle) or treated 
with anti-gp69 on days 0 and 3 (closed square). On day 14, spleens 
were removed and CTL responses determined in vitro by5 day stimula- 
tion with mitomycin c-treated B6D2Fl (H-27 spleens (5 x IO’ per 5 x 
IO8 responder cells). CTL responses were determined by %r release 
assay using P615 (H-q cells as the tumor target cell line. All syngeneic 
responses were not significant. The figure also indicates the response 
of naive C57BU6 to in vitro challenge with B6D2Fl spleen cells (closed 
triangle). 
(C) Antigp39 does not affect the H-2b anti-H-2 CTL response after in 
vitro challenge with H9%xpressing cells. C57BU6 were immunized 
intravenously with 100 x l(P B6D2Fl spleen cells on day 0, and then 
untreated (closed circle) or treated with antigp69 on days 0 and 3 
(closed square). On day 14, spleens were removed and CTL responses 
determined in vitro by5 day stimulation with mitomycin c-treated CBA 
(H-27 spleens (5 x IQ per 5 x IO’ responder cells). CTL responses 
were determined by %r release assay utilizing SL6 (H-29 cells as the 
target cell line. All syngeneic responses were not significant. The figure 
also indicates the response of naive C57BU6 to in vitro challenge with 
B6D2Fl spleen cells (closed triangle). 
whether tolerance was induced, spleen cells from the re- 
cipient mice were transferred into an Fl (H-2W), which 
should induce an in vivo GVH response. Mice then were 
assayed for the development of anti-H-2d CTL activity. Re- 
sults indicated that H-2b mice that were administered Fl 
cells and anti-gp39 were unable to generate anti-H-2d CTL 
responses in vivo (Figure 8A). In addition, the anti-H-2d 
CTL responses of C57BU6 spleen cells generated in vitro 
from mice administered Fl cells were greatly reduced 
compared with the CTL response of naive C57BU6 spleen 
cells (Figure 88). Spleen cells from mice that were admin- 
istered Fl (H-27 spleen cells were rendered unresponsive 
specifically to the H-2“ alloantigen, since the in vitro CTL 
response to a third party alloantigen (H-p) was unaffected 
(FigureBC). Experiments performed using either Fl Bcells 
or Fl spleen cells to tolerize the host to the disparate 
alloantigen have yielded indistinguishable results. 
This study shows that the coadministration of antigp39 
and allogeneic B cells reduced the MLR and CTL response 
to the alloantigen; the prior activation of the allogeneic B 
cells with LPS diminished their tolerogenic potential when 
coadministered with antigp39; antigp39 has no impact 
on the induction of CTL to allogeneic tumor cells or thymo- 
cytes; alloantigens on the allogeneic B cells independently 
tolerized alloreactive CD4 and CD8 T cells; the administra- 
tion of allogeneic B cells (in the absence of antigp39) 
to gp39 knockout mice rendered them hyporesponsive to 
alloantigen; and the coadministration of allogeneic B cells 
and anti-gp39 induced a state of profound in vivo CTL 
unresponsiveness. The extent of unresponsiveness in the 
CTL compartment that resulted from the administration of 
alloantigen and anti-gp39 was demonstrated by the inabil- 
ity to induce a GVH CTL response from tolerized mice. 
An important issue raised by these studies is the mecha- 
nism of how antigp39 interferes with the development of 
allospecific MLR and CTL responses. The administration 
of allogeneic B cells alone induced slightly heightened 
MLR: vigorous primary CTL responses in vivo and en- 
hanced secondary CTL responses in vitro. The coadminis- 
tration of allogeneic B cells and anti-gp39 reduced the 
MLR, ablated the in vivo CTL response, and reduced the 
secondary CTL response below that observed from un- 
primed mice. All of these data suggest that the coadminis- 
tration of anti-gp39 and allogeneic B cells inactivated both 
the CD4 and CD8 alloreactive precursors. Although these 
experiments do not provide a definitive answer to the 
mechanism of immunosuppressive action by antigp39, it 
is evident that the inhibitory effect of antigp39 is depen- 
dent upon the nature of cells used for immunization. Since 
CTL responses to allogeneic tumor cells and thymocytes 
were intact in the presence of antigp39, the antibodycan- 
not be simply deleting or anergizing alloreactive CTL or 
alloreactive helper T cells required for the response. Fur- 
thermore, the fact that anti-gp39 administration does not 
interfere with the priming of sheep red blood cell-specific 
helper T cells (Foy et al., 1993), block the antigen-induced 
expression of lymphokines in situ (Van den Eertwegh et 
al., 1993), or skew the pattern of lymphokine expression 
in situ (Van den Eertwegh et al., 1993) strongly suggests 
that there are no or minimal direct effects of antigp39 on 
T cells. Furthermore, the fact that mice genetically defi- 
cient in the expression of gp39 are rendered hyporespon- 
sive to alloantigen by the administration of allogeneic B 
cells all supports the hypothesis that in the absence of a 
CD40 signal, B cells are tolerogenic. 
Studies using a panel of allogeneic cells to induce toler- 
ance provided clues to the mechanism of immunosuppres- 
sion imposed by anti-gp39. The fact that class I and class 
B Cells Are Tolerogenic Without a CD40 Signal 
651 
II MHCdeficient B cells selectively tolerized the CD4 and 
CD8 compartments, respectively, suggest that the anti- 
gp39 was not suppressing allospecific responses by in- 
terfering with alloreactive helper T cell function. These 
data indicate that the tolerance in these two compartments 
was induced independently. Furthermore, the fact that al- 
logeneic LPS blasts were not as tolerogenic as nonacti- 
vated B cells indicated that the activation state of the B 
cell was critical for it to elicit unresponsiveness. Finally, 
the hypothesis that antigp39 was mediating its effects by 
simply blocking gp39 function (and not delivering direct 
signals to the T cell) was supported by the diminished 
allospecific responsiveness observed in gp39deficient 
mice that were administered allogeneic B cells, 
The data presented are consistent with the hypothesis 
that antigp39 prevents the up-regulation of costimulatory 
molecules at a critical moment when cognate interactions 
between host T cells and the allogeneic B cells are oc- 
curring. The first tenet of this hypothesis is that gp39 is 
critical in the regulation of B7-l/B7-2 during cognate inter- 
actions. It has been shown that during T-B cell interactions, 
antigen recognition via TCR induces the up-regulation of 
gp39 on the antigen-specific T cell; and, in turn, gp39 in- 
duces the up-regulation of 87-l and 87-2 on the cognate 
,B cell (Roy et al., 1994). Therefore, gp39 blockade pre- 
vents the up-regulation of 87-l and 87-2. Another tenet 
of this hypothesis is that the level of 87-1187-2 expression 
is a crucial regulator of tolerance versus immunity. Sup- 
portive of this idea is that blocking of B7-1187-2 function 
results in T cell tolerance, as reviewed by Linsley and 
Ledbetter (1993). For example, studies by Turka and co- 
workers have shown that the coadministration of alloge- 
neic spleen cells and CTLA-419, a soluble receptor that 
blocks 87-l and 87-2 binding to their coreceptors, induced 
a state of prolonged transplantation tolerance and fostered 
the long-term engraftment of cardiac allografts (Lin et al., 
1993; Bolling et al., 1994). Therefore, the tolerance in- 
duced by the blockade of 87-l and 87-2 seems to elicit 
similar tolerogenic effects on the host as anti-gp39 admin- 
istration. All of these approaches appear to take advan- 
tage of the central role of costimulation to tip the balance 
of the immune system towards unresponsiveness. 
Another issue raised as a result of these studies focuses 
on the inability of professional APC in the B cell inoculum 
to prevent the induction of tolerance. The studies reported 
show that the administration of highly purified Percoll- 
fractionated resting B cells or allogeneic T-depleted or 
nondepleted splenocytes induced allospecific unrespon- 
siveness. These data show that low numbers of macro- 
phages and activated B cells (likely 3%-5% of the popula- 
tion) cannot prime in the presence of antigp39 and resting 
B cells. The dominant effect of the resting B cells in the 
preparation is also consistent with the effect of antigp39 
on GVHD (Durie et al., 1994). That is, brief administration 
of anti-gp39 blocks the occurrence of both the acute and 
chronic forms of GVHD for the length of the experiments 
(>I4 weeks). In this case, tolerance was induced even 
when all of the host APCs (macrophages, dendritic cells) 
could potentially present alloantigen. We speculated that 
the large number of quiescent host B cells (imposed by 
antigp39) tolerized the donor T cells, rendering them toler- 
ant and preventing GVHD. In effect, the resting B cells 
preempted priming by host APC. An alternative explana- 
tion for the tolerogenic effects that anti+39 imposed on 
. . 
require CD49 triggering to upregulate costimulatory mole- 
cule expression and become proficient APCs. Support for 
a central role of gp39 in the up-regulation of dendritic cell 
APC function has been recently provided by a series of 
studies that show that freshly isolated dendritic cells are 
deficient in APC function or costimulatory molecule ex- 
pression and that CD49 triggering up-regulated APC func- 
tion (Caux et al., 1994; lnaba et al., 1994). Therefore, anti- 
gp39 administration may globally down-regulate APC 
function. 
The practical significance of ant@39 and B cell- 
induced allo-unresponsiveness to the transplantation of 
allogeneic tissue has been demonstrated by Parker and 
coworkers (Parker et al., submitted). Mice, which were 
rendered tolerant to alloantigen by the coadministration 
of allogeneic B cells and antigp39, accepted allogeneic 
pancreatic 3 islet cells. Upon histological examination of 
the site of implantation there was no indication of any in- 
flammatory processes, which was consistent with the long 
term engraftment observed. Although antigp39 treatment 
alone did extend the longevity of the transplant in some 
mice, the combined administration of antigp39 and allo- 
geneic Bcells permitted the long-term survival of the tissue 
allografts in virtually all of the mice. Given these data, it 
is hopeful that the combined administration of antigp39 
and donor lymphocytes may enhance the success of allo- 
geneic tissue or organ grafts in humans. 
ExPwlmsntal Procedures 
Anlmalr 
Female 8 to Eweek-old BALBlc, C57BU6, CSBFl, BlO.BR, B6D2F1, 
and CBA/J, fllrn (Koller et al., 1990) and class II knockout mice (Cos- 
grove et al., 1991) were obtained from the Jackson Laboratory (Bar 
Harbor, Maine). Animals were maintained in the specific pathogen-free 
animal facility at Dartmouth Medical School. The gp39 knockout mice 
(H-3 were produced as previously described (Ku et al., 1994). 
Prepamtlon of B Calla 
T cell-depleted splenocytes were prepared by treating single cell 
splenic suspensions with ammonium chloride treatment to lyse eryth- 
rocytes. T cells were cytotoxically eliminated by treatment of the spleen 
cells with anti-Thyl.2 (HD-13-4; American Type Culture Collection 
[ATCC], Rockville Pike, Maryland) (Marshak-Rothstein et al., 1979). 
anti-CD4 antibodies (RL172/4) (Mizouchi et al., 1969) and rabbit com- 
plement. Viable cells were isolated by flotation on FicolCHypaque 
(Sigma Chemical Company, St. Louis, Missouri). Cells isolated were 
typically X5% mouse immunoglobulin positive, had a uniform low 
degree of near forward light scatter, and were unresponsive to conca- 
navalin A. Resting splenic B cells were prepared by sedimentation on 
discontinuous Percoll gradients, as described previously (DeFranco 
et al., 1962). Cells isolated from the 70%-75% (density of 1.067- 
1.097) Percoll interface were typically 37% mouse immunoglobulin 
positive, had a uniform low degree of near forward light scatter, and 
were unresponsive to concanavalin A. 
Antlbodk 
Antigp69, a hamster anti-mouse antibody (MRl; Noelle et al., 1992) 
was produced as ascites in SCID mice and purified by ion exchange 
high pressure liquid chromatography (HPLC). Hamster serum was ob- 
tained from Pel-Freez Biologic&, Rogers, Arkansas, and the immu- 
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noglobulin G fraction purified by ion exchange HPLC. Anti-Thyl.2 was 
used directly from ascites prepared from ATCC clone HO134 and 
ATCC clone RL172/4, which were tftered for the depletion of thymo- 
cytes in the presence of complement. 
Target Cell Lines 
E female Kl (H-26, T cell lymphoma derived from C57BU6 strain) 
(Green et al., 1979), P615 (If@, mastocytoma, derived from DBA/2J 
strain, obtained originally from ATCC), SL6 (H-2, a spontaneous T 
cell leukemia derived from AKR strain) (Nowinski et al., 1977), and 
EL4 (H-26, T cell lymphoma derived from C57BU6N strain) were used 
as target cells lines in the “Cr release assay. 
Immunization Protocols 
Recipient mice were administered 30-50 x IO allogeneic splenic 
B cells or allogeneic thymocytes, as a source of T cells. Cells were 
administered intravenously in balanced salt solution. These mice were 
untreated or treated with antigp39 (250 &mouse for 2 days) on days 
0, 2, and 4. On day 6, spleens were removed and used as effector 
cells in the standard 61Cr release assay (Durfe et al., 1994). Tumor 
responses were determined by administering 5 x 10 P615 cells intra- 
peritoneally. Recipient (C57BU6) mice were treated with antigp39 or 
Hlg on days 0,2, 4,6,8, and IO. On day 12, H-2b anti-H-2” responses 
were measured in a CTL assay. 
MLR 
Spleens from in viva-primed animals treated with either antiip39 or 
Hlg were removed and used as responders. For stimulators, spleen 
cells were prepared from either syngeneic mice or donor allogeneic 
mice. In the case of third party responses, spleen cells were prepared 
from BlO.BR mice (H-a. Stimulator cells were treated with 25 &ml 
mitomycin C (Sigma) for 20 min at 37*C and then washed extensively 
in balanced salt solution. Final cell preparations were resuspended 
in MLR media, RPM1 1646 with 25 mM HEPES (Bii Whittaker, Walk- 
ersville, Maryland), containing 10% fetal calf serum (JRH Biosciences, 
Lenexa, Kansas), 500 U/ml penicillin. and 5000 U/ml streptomycin 
(Sigma), 2 mM Lglutamine (Sigma), and 50 mM 2-mercaptoethanol 
(EioRad Laboratories, Hercules, California). Responders were resus- 
pended at 4 x 10E/ml and stimulators at 2 x lO”/ml and plated in 
ratios of 21 in U-bottomed 96-well plates. Each ratio was set up in 
triplicate and cultured for 3 days. During the last 6 hr of culture, 
PH]thymidine, 1 f&i/well was added. Cells were harvested and thymi- 
dine incorporation was determined by scintillation counting. 
In Vitro Culture ot CTL and Assessment of CTL Activity 
Spleen cells from in viva-primed animals treated with antigp39 or 
untreated were used as responders (5 x l(r/ml) for in vitro challenge. 
In vitro culture of CTL was performed by culturing syngeneic or alloge- 
neic 5 x Iv/ml splenic B cell (anti-Thyl.2 and complement treatment) 
stimulators (mitomycin C-treated, 25 ug/ml, 20 min at 37OC) and re- 
sponder cells groups in complete enriched RPM1 1640 medium (Bio 
Whittaker) containing 10% fetal calf serum (Hyclone Laboratories, b 
gan, Utah), 1 mM sodium pyruvate (Bio Whittaker), 1 x nonessential 
amino acids (Bio Whittaker), 1 x 106 M P-mercaptoethanol (BioRad 
Laboratories), 2 mM L-glutamine (Sigma), 500 U/ml penicillin, and 
5000 U/ml streptomycin (Sigma). After Sdays, the responder cells were 
harvested, dead cells were removed by centrifugation on a density 
gradient, and the resulting live cells were used as effecters in a CTL 
assay against the relevant target cell lines. 
In vitro CTL activity was measured by the standard $‘Cr release 
assay as previously described (Durie et al., 1994). 
Acute GVHD 
C57BU6 mice were administered 100 x IO spleen cells from B6D2Fl 
(C57BU6 x DBAI2)Fl, H-2b”d) intravenously on day 0 and either 
treated with antigp39 on days 0 and 3 or untreated. On day 14, spleen 
cells were removed from these recipient animals and 20 x 10 cells 
were used as responders in an MLC using B6D2Fl or CBAlJ mito- 
mycin C-treated spleen cells as the stimulators. The remaining spleen 
cells (approximately 60 x 1CP cells) were used to immunize B6D2Fl 
recipients in a model of acute GVHD. Induction of GVHD was mea- 
sured by determining the H-2b anti-H-p CTL response characteristic 
of acute GVHD. 
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